Frank Reetz

Frank Reetz has extensive work experience in the pharmaceutical and biotech industries. Frank is currently serving as the Vice President and Global Program Head at MorphoSys, overseeing the development of Pelabresib and Tafasitamab. Before joining MorphoSys, they held various leadership positions at Bayer, including Global Program Head for Rare Diseases, Cell and Gene Therapy, and Hemophilia projects. Frank was also involved in project management for oncology and hemophilia programs at Bayer. Additionally, they have experience in bio operations, external development, and laboratory management.

Frank Reetz completed their Master of Science degree in Chemistry from RPTU Kaiserslautern-Landau between 1991 and 1997. Frank then pursued a Doctor of Philosophy (PhD) degree with a focus on Molecular Toxicology at DKFZ German Cancer Research Center from 1997 to 2000.